ContextAmong cancer-free women aged 35 years or older, tamoxifen reduced the incidence
of estrogen receptor (ER)–positive but not ER-negative breast cancer. The effect of …

Purpose Chemoprevention with a selective estrogen receptor modulator (tamoxifen or
raloxifene) is a non-surgical option offered to high-risk women to reduce the risk of breast …

The purpose of our study was to review the evidence for the efficacy of surveillance for early
detection, bilateral prophylactic mastectomy, prophylactic oophorectomy and …

Purpose To determine whether adjuvant tamoxifen treatment for breast cancer (BC) is
associated with reduced contralateral breast cancer (CBC) risk for BRCA1 and/or BRCA2 …

Background Women with a mutation in BRCA1 or BRCA2 have a high risk of developing
breast cancer and of contralateral cancer after the initial diagnosis of breast cancer …

Background Hormone therapy (HT) is commonly given to women to alleviate the climacteric
symptoms associated with menopause. There is concern that this treatment may increase …

Purpose To review new evidence on the benefits and harms of risk assessment, genetic
counseling, and genetic testing for BRCA-related cancer in women for the US Preventive …

Genetic testing for mutations in BRCA1 and BRCA2 is available in Canada for women with a
significant family history of breast cancer. For the majority of tested women, a BRCA1 or …

Several options for cancer prevention are available for women with a BRCA1 or BRCA2
mutation, including prophylactic surgery, chemoprevention and screening. The authors …

Importance Prophylactic bilateral salpingo-oophorectomy is recommended
forBRCA1mutation carriers to prevent ovarian cancer. Whether or not hormone replacement …